Minimal removal of raltegravir by hemodialysis in HIV-infected patients with end-stage renal disease

Antimicrob Agents Chemother. 2010 Jul;54(7):3047-8. doi: 10.1128/AAC.00363-10. Epub 2010 May 3.

Abstract

Little is known about raltegravir removal by hemodialysis in patients with end-stage renal disease (ESRD). We therefore measured raltegravir concentrations in plasma in pre- and postdialyzer blood samples from 2 ESRD HIV-infected patients. The hemodialysis extraction ratio and raltegravir hemodialysis clearance were 5.5% and 9.1 ml/min in patient 1 and 9.5% and 19.1 ml/min in patient 2, respectively. Our results suggest minimal raltegravir removal by hemodialysis with no specific raltegravir dosage adjustments required in HIV-infected patients undergoing hemodialysis.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • HIV Infections / blood*
  • HIV Infections / drug therapy*
  • HIV Integrase Inhibitors / blood*
  • HIV Integrase Inhibitors / therapeutic use*
  • Humans
  • Kidney Failure, Chronic / blood*
  • Kidney Failure, Chronic / therapy*
  • Male
  • Middle Aged
  • Pyrrolidinones / blood*
  • Pyrrolidinones / therapeutic use*
  • Raltegravir Potassium
  • Renal Dialysis / methods*

Substances

  • HIV Integrase Inhibitors
  • Pyrrolidinones
  • Raltegravir Potassium